WMJ Vol 122 Issue 2: Skin and Soft Tissue Infections in Young Infants

ABSTRACT

Introduction: The management of young infants with skin and soft tissue infection is not well-defined.

Methods: We performed a survey study of pediatric hospital medicine, emergency medicine, urgent care, and primary care physicians to assess the management of young infants with skin and soft tissue infection. The survey included 4 unique scenarios of a well-appearing infant with uncomplicated cellulitis of the calf with the combination of age ≤ 28 days vs 29–60 days and the presence vs absence of fever.

Results: Of 229 surveys distributed, 91 were completed (40%). Hospital admission was chosen more often for younger infants (≤ 28 days) versus older infants regardless of fever status (45% vs 10% afebrile, 97% vs 38% febrile, both P < 0.001). Younger infants were more likely to get blood, urine, and cerebrospinal fluid studies (P < 0.01). Clindamycin was chosen in 23% of admitted younger infants compared to 41% of older infants (P < 0.05).

Conclusions: Frontline pediatricians appear relatively comfortable with outpatient management of cellulitis in young infants and rarely pursued meningitis evaluation in any afebrile infants or older febrile infants.

Intended Audience

The intended audience for this journal-based activity is healthcare providers caring for the people and communities of Wisconsin and beyond.

Learning Objectives

As a result of this journal-based activity, learners, as members of the healthcare team, will be able to:

  1. Summarize what is known about the management of young infants with skin and soft tissue infection, based on the literature reviewed in the article.
  2. Explain findings of this survey study exploring the preferred diagnostic and management approach to a young infant with uncomplicated cel­lulitis among physicians in the clini­cal areas of pediatric hospital medicine, pediatric primary care, pediatric emergency medicine, and pediatric urgent care.
  3. Elaborate on how the study findings apply to the learner’s clinical practice.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™
Registration opens: 
04/04/2024
Course expires: 
04/03/2025
Cost:
$0.00
Part of: 
Wisconsin Medical Journal Volume 122
Rating: 
0

FACULTY DISCLOSURE

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the  speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE).  In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.

For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.

Name of IndividualIndividual's Role in Activity

Financial Relationship Disclosure

Discussion of
Unlabeled/Unapproved
Uses of Drugs/Devices
in Presentation?

Marianna Shershneva, MD, PhDAccreditation SpecialistNo relevant relationships with ineligible companies to discloseNo
Sheila Swartz, MD, MPHAuthorNo relevant relationships with ineligible companies to discloseNo
Leah Cotter, MDAuthorNo relevant relationships with ineligible companies to discloseNo
Anika Nelson, MDAuthorNo relevant relationships with ineligible companies to discloseNo
Jian Zhang, PhDAuthorNo relevant relationships with ineligible companies to discloseNo
Ke Yan, PhDAuthorNo relevant relationships with ineligible companies to discloseNo
Michelle L Pickett, MD, MSAuthorNo relevant relationships with ineligible companies to discloseNo
Barry J PelzReviewerNo relevant relationships with ineligible companies to discloseNo
Richard H. Strauss, MDReviewerNo relevant relationships with ineligible companies to discloseNo
Fahad Aziz, MDEditorNo relevant relationships with ineligible companies to discloseNo
    

 

   

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on, patients.

The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.

Discloser List CME Internal Report

Accreditation

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison ICEP and the Wisconsin Medical Journal.  The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation Statements

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Continuing Education Units

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Free, current version of Chrome, Firefox, Safari, or Edge. Some older browsers and Microsoft Internet Explorer could produce error messages or not display the content correctly. 

Free, current version of Adobe Acrobat Reader or other .pdf reader.